

Haematologica
HAEMATOL/2016/154377
Version 3

Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase 2 study

Vincent Ribrag, Won Seog Kim, Reda Bouabdallah, Soon Thye Lim, Bertrand Coiffier, Arpad Illes, Bernard Lemieux, Martin J.S. Dyer, Fritz Offner, Zakia Felloussi, Ioana Kloos, Ying Luan, Remus Veza, Thorsten Graef, and Franck Morschhauser

Disclosures: VR: honoraria from Servier, consulting or advisory role for Gilead, Nanostring, Infinity, Bristol-Meyers Squibb, research funding from Argenx, travel expenses from Roche and Bristol-Meyers Squibb; BC: consulting or advisory role with Celgene, Novartis, Celltrion, Pfizer; travel expenses from Celgene, Celltrion, and Pfizer; AI: honoraria and consulting or advisory role for Roche, Takeda, and Janssen, research funding from Takeda, Janssen, Amgen, Novartis, Pharmacyclics LLC, an AbbVie Company, Gilead, and Seattle Genetics, and travel expenses from Bristol-Myers Squibb, Janssen, and Roche; BL: consulting or advisory role for Roche, Janssen Ortho, Servier Canada, and Celgene; MJSD: consulting or advisory role for Roche, research funding from ONO and Gilead, speakers' bureau for Roche, and travel expenses from Gilead; FO: consulting or advisory role for GlaxoSmithKline and Novartis; IK: patents or intellectual property with Servier; YL: employment with Pharmacyclics LLC, an AbbVie company, and stock ownership of AbbVie; RV: employment with Pharmacyclics LLC, an AbbVie company, and stock ownership of AbbVie; TG: employment and patents or intellectual property for Pharmacyclics LLC, an AbbVie company, and stock ownership of AbbVie; FM: consulting role for Servier and Gilead, advisory board and honoraria for scientific lectures for Roche, Celgene, Bristol-Meyers Squibb, Janssen. WSK, RB, STL, and ZF have no potential conflicts of interest to disclose.

Contributions: VR, FM, IK, RV, and TG were responsible for the study design. VR, RV, and TG were responsible for data interpretation and data analysis. VR, WSK, RB, STL, BC, AI, BL, MJSD, FO, IK, and FM participated in the study and enrolled patients. ZF, IK, and YL confirmed data accuracy and compiled data for summation and analysis. YL analyzed the data. All authors carefully reviewed, edited, and approved the final manuscript.